Immune response to tuberculosis (WP4197)
This pathway is published in "The human immune response to tuberculosis and its treatment: a view from the blood" (PMID: 25703554). Proteins on this pathway have targeted assays available via the [https://assays.cancer.gov/available_assays?wp_id=WP4197 CPTAC Assay Portal].
AuthorsAndra Waagmeester , Egon Willighagen , Kristina Hanspers , and Eric Weitz
Discuss this pathway
- A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection (2020).
- Bioinformatics and systems-biology analysis to determine the effects of Coronavirus disease 2019 on patients with allergic asthma (2022).
Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.
- An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Berry MPR, Graham CM, McNab FW, Xu Z, Bloch SAA, Oni T, et al. Nature. 2010 Aug 19;466(7309):973–7. PubMed Europe PMC Scholia
- Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. Cliff JM, Lee JS, Constantinou N, Cho JE, Clark TG, Ronacher K, et al. J Infect Dis. 2013 Jan 1;207(1):18–29. PubMed Europe PMC Scholia
- Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. Bloom CI, Graham CM, Berry MPR, Rozakeas F, Redford PS, Wang Y, et al. PLoS One. 2013 Aug 5;8(8):e70630. PubMed Europe PMC Scholia
- The human immune response to tuberculosis and its treatment: a view from the blood. Cliff JM, Kaufmann SHE, McShane H, van Helden P, O’Garra A. Immunol Rev. 2015 Mar;264(1):88–102. PubMed Europe PMC Scholia